tbuckley/cabot-search huggingface dataset:
Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer
Authors: Sara Duhachek-Muggy, Yue Qi, Randi Wise, Linda Alyahya, Hui Li, Jacob Hodge, Anna Zolkiewska
Journal: Molecular Cancer (2017)

ADAM12 is upregulated in human breast cancers and is a predictor of chemoresistance in estrogen receptor-negative tumors. ADAM12 is induced during epithelial-to-mesenchymal transition, a feature associated with claudin-low breast tumors, which are enriched in cancer stem cell (CSC) markers. It is currently unknown whether ADAM12 plays an active role in promoting the CSC phenotype in breast cancer cells. ADAM12 expression was downregulated in representative claudin-low breast cancer cell lines, SUM159PT and Hs578T, using siRNA transfection or inducible shRNA expression. Cell characteristics commonly associated with the CSC phenotype in vitro (cell migration, invasion, anoikis resistance, mammosphere formation, ALDH activity, and expression of the CD44 and CD24 cell surface markers) and in vivo (tumor formation in mice using limiting dilution transplantation assays) were evaluated. RNA sequencing was performed to identify global gene expression changes after ADAM12 knockdown. We found that sorted SUM159PT cell populations with high ADAM12 levels had elevated expression of CSC markers and an increased ability to form mammospheres. ADAM12 knockdown reduced cell migration and invasion, decreased anoikis resistance, and compromised mammosphere formation. ADAM12 knockdown also diminished ALDEFLUOR+ and CD44hi/CD24-/lo CSC-enriched populations in vitro and reduced tumorigenesis in mice in vivo. RNA sequencing identified a significant overlap between ADAM12- and Epidermal Growth Factor Receptor (EGFR)-regulated genes. Consequently, ADAM12 knockdown lowered the basal activation level of EGFR, and this effect was abolished by batimastat, a metalloproteinase inhibitor. Furthermore, incubation of cells with exogenously added EGF prevented the downregulation of CD44hi/CD24-/lo cell population by ADAM12 knockdown. These results indicate that ADAM12 actively supports the CSC phenotype in claudin-low breast cancer cells via modulation of the EGFR pathway.
Integration-Mediated Activation of PRDM16 and HMGA2 in Multiple Clones without Adverse Hematopoietic Consequences Following Transplant of Autologous MGMTP140K Gene-Modified CD34+ Cells
Authors: Jennifer E Adair, Brian C Beard, Grant Trobridge, Frederic Bushman, Maciej M Mrugala, Hans-Peter Kiem
Journal: Blood (2011)
A Cell-Autonomous Defect of Bone Marrow Hematopoietic Stem/Progenitor Cells and Impaired Stromal Function in FA-a Patients
Authors: Xiaoling Zhang, Xun Shang, Fukun Guo, Kim Murphy, Michelle Kirby, Patrick Kelly, Lilith Reeves, Franklin O Smith, David A. Williams, Yi Zheng, Qishen Pang
Journal: Blood (2008)
ß-Catenin siRNA Successfully Suppressed the Progression of Multiple Myeloma in In Vivo Mouse Model.
Authors: Eri Kawata, Eishi Ashihara, Ruriko Tanaka, Asumi Yokota, Yoshihide Murotani, Miki Taniguchi, Yuri Kamitsuji, Junya Kuroda, Tohru Inaba, Chihiro Shimazaki, Shinya Kimura, Taira Maekawa
Journal: Blood (2007)
ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
Authors: Jody C. Chuang, Henning Stehr, Ying Liang, Millie Das, Jane Huang, Maximilian Diehn, Heather A. Wakelee, Joel W. Neal
Journal: Journal of Thoracic Oncology (2017)
BIK (Bcl2-Interacting Killer) CpG Methylation Status in Multiple Myeloma Patients: a Potential Predictor of Relapsed/Refractory Disease.
Authors: Eleftheria Hatzimichael, Aggeliki Dasoula, George Dranitsaris, Amalia Vassou, Justin Stebbing, Tim Crook, Konstantinos Bourantas
Journal: Blood (2009)
Low Serum Folate Levels as a Risk Factor for Non-Hodgkin’s Lymphoma.
Authors: HeeNam Kim, Min-Ho Shin, Yeo-Kyeoung Kim, Il-Kwon Lee, Deok-Hwan Yang, Je-Jung Lee, Kyeong-Soo Park, Jin-Su Choi, Hyeoung Joon Kim
Journal: Blood (2007)
Prognostic significance of QOL deterioration during early lung cancer survivorship: Secondary analysis of RTOG 0212 and 0214.
Authors: V. Gondi, R. Paulus, D. Bruner, C. A. Meyers, E. Gore, A. H. Wolfson, M. Werner-Wasik, H. Choy, B. Movsas
Journal: Journal of Clinical Oncology (2011)

6061 Background: We assessed the association of deterioration (D) in patient-reported quality of life (QOL) with survival following curative-intent treatment for limited-disease small cell lung cancer (LD-SCLC) and locally advanced non-small cell lung cancer (LA-NSCLC). Methods: Patients with LD-SCLC and LA-NSCLC were enrolled on RTOG trials 0212 and 0214, respectively. QOL was assessed as a secondary endpoint using EORTC QLQ-C30 and BN20 at baseline (following locoregional therapy but before PCI or observation) and at 6 and 12 months (mos) follow-up. D was defined compared to baseline using the reliable change index method and correlated with overall survival and the cumulative incidence of brain and distant metastases using the Cox proportional hazards and Fine and Gray’s proportional hazards models, respectively. Covariates included age, gender, race, partner status, education, Zubrod performance score, histology, PCI use, and PCI dose. Results: 552 (91%) of the 604 eligible patients accrued to RTOG 0212 and RTOG 0214 had baseline QOL assessments and were included in this pooled analysis. Compliance with QOL assessments (66% at 6 mos and 54% at 12 mos) did not differ between RTOG 0212 and 0214. After adjusting for baseline QOL score and covariates, D in global health status/QOL at 6 and 12 mos, fatigue at 6 and 12 months, and cognitive functioning at 12 months was associated with worse overall survival, compared to no deterioration/improvement (ND) (Table). D in global health status/QOL (1.82, 1.28-2.59, p=0.0009) and fatigue (1.61, 1.15-2.27, p=0.006) at 6 months was also associated with increased risk of distant metastasis. Conclusions: Longitudinal deterioration in global health status/QOL, fatigue and cognitive functioning at 6 and 12 months after definitive treatment for LD-SCLC or LA-NSCLC is potentially an early surrogate marker for poor overall survival. Global Health Status/QOL Fatigue Cognitive functioning 6 mos 12 mos 6 mos 12 mos 12 mos D ND D ND D ND D ND D ND Median survival (mos) 21.4 37.2 30.0 38.6 27.4 33.0 33.0 42.7 28.5 49.0 Adjusted hazard ratio 2.41 2.22 1.71 1.87 1.88 95% confidence interval 1.70-3.43 1.39-3.56 1.20-2.43 1.15-3.04 1.18-3.00 P <0.0001 0.0009 0.003 0.01 0.008
Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial
Authors: Utz Krug, Carsten Muller-Tidow, Matthias Stelljes, Maria Cristina Sauerland, Achim Heinecke, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach, Jan Braess, Karsten Spiekermann, Sarah Volpert, Peter Staib, Andreas Grüneisen, Wolfgang Kern, Albrecht Reichle, Wolf-Dieter Ludwig, Leopold Balleisen, Hartmut Eimermacher, Carlo Aul, Herbert Rasche, Eva Lengfelder, Eckhard Thiel, Joachim Kienast, Hubert Serve, Bernhard Josef Woermann, Wolfgang Hiddemann, Wolfgang E. Berdel, Thomas Buchner
Journal: Blood (2011)
TET2 Mutations in Secondary Acute Myeloid Leukemias: A French Retrospective Study
Authors: Olivier Kosmider, Véronique De Mas, Eric Delabesse, Pascale Cornillet-lefevre, Odile Blanchet, Christian Récher, Sophie Raynaud, Catherine Lacombe, Olivier Bernard, Norbert Ifrah, Francois Dreyfus, Michaëla Fontenay on behalf of the GOELAMS
Journal: Blood (2010)
Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial.
Authors: Chris Parker, Jose E. Garcia-Vargas, C. Gillies O'Bryan-Tear, Fang Fang, Nicholas J. Vogelzang
Journal: Journal of Clinical Oncology (2013)

5060 Background: In the updated analysis of the ALSYMPCA study, Ra-223 significantly improved median survival by 3.6 mo vs placebo (Pbo) in 921 CRPC patients (pts) with bone mets (HR = 0.695; 95% CI, 0.581-0.832; p = 0.00007) and had a highly favorable safety profile (Parker et al. ASCO 2012). The hematologic safety profile and results from a post hoc analysis assessing prognostic factors for changes in hematologic parameters in ALSYMPCA pts are presented. Methods: Pts were randomized 2:1 to 6 injections (inj) of Ra-223 (50 kBq/kg IV) q4wk or matching Pbo and stratified by prior docetaxel (D) use, total alkaline phosphatase (tALP), and current bisphosphonate use.Multivariate regression analysis was performed to explore the relationship of 6 baseline factors (Table) with maximum % change of hematologic parameters from baseline up to 24 wk on treatment (tx). Results: The updated analysis included 901 pts (safety population; Ra-223, n = 600; Pbo, n = 301). Overall grade 3/4 AEs were similar between Ra-223 and Pbo groups, with neutropenia in 2% and 1%, thrombocytopenia in 6% and 2%, and anemia in 13% and 13% of Ra-223 and Pbo groups, respectively. Tx with Ra-223, prior D use, extent of disease (EOD) &gt; 6 bone mets, and tALP ≥ 220 U/L, but not current bisphosphonate use, were associated with decreases from baseline in hemoglobin (Hb), neutrophils, or platelets; prior EBRT to bone for pain was associated with an increase. The significance of the relationship between baseline factors and changes in hematologic parameters is summarized in the Table. Conclusions: Overall, there was a low risk for hematologic AEs with Ra-223 tx in CRPC pts with bone mets. The strongest prognostic factors for decreases in neutrophils and platelets were Ra-223 tx and prior D use. Baseline tALP ≥ 220 U/L was a strong predictor of decrease in Hb. Clinical trial information: NCT00699751. [Table: see text]
A Novel β-catenin Inhibitor, AV65 Suppresses the Growth of CML Cell Lines Which Acquire Imatinib-Resistance Because of Abl Kinase Domain Mutations Including T315I and Hypoxia-Adaptation.
Authors: Rina Nagao, Shinya Kimura, Eishi Ashihara, Miki Takeuchi, Ruriko Tanaka, Asumi Yokota, Hisayuki Yao, Jeffrey W Strovel, Wieslaw M Cholody, Taira Maekawa
Journal: Blood (2008)
International Consensus Criteria for Tyrosine Kinase Inhibitor Response and Outcome of Allogeneic Stem Cell Transplantation for CML
Authors: Sairah Ahmed, Rima M Saliba, Marcos De Lima, Tobi DeAnn Fisher, Gabriela Rondon, Partow Kebriaei, Amin M Alousi, Chitra M Hosing, Qaiser Bashir, Borje Andersson, Richard E. Champlin
Journal: Blood (2012)
RUNX1 TAD and RHD Mutations Found in SCN/AML Differentially Affect HSPC Expansion in Conjunction with Truncated CSF3 Receptors
Authors: Julia C. Obenauer, Paulina M. H. van Strien, Remco M. Hoogenboezem, Marry M. van den Heuvel-Eibrink, Ivo P. Touw
Journal: Blood (2015)
IMPS-21EFFECT OF rQNestin 34.5 ONCOLYTIC HERPES VIRUS ON IMMUNE CHECKPOINT GENE EXPRESSION IN GLIOBLASTOMA CELLS AND EVALUATION OF THERAPEUTIC EFFICACY
Authors: Maria-Carmela Speranza, Kazue Kasai, Johanna Kaufmann, Hiroshi Nakashima, Sean Lawler, E. Antonio Chiocca
Journal: Neuro-Oncology (2015)

There has been a recent surge of interest in cancer immunotherapies due to newly FDA approved immunologic treatments based on targeting immune checkpoint inhibition pathways. Multiple preclinical and clinical trials combining immunostimulatory approaches with immune checkpoint inhibition are also underway, reinforced by fairly dramatic anticancer responses in animal models and early clinical human trials. Because oncolytic viruses (OVs) can lead to improved presentation of tumor antigens, they may be potentially useful in combination with immune checkpoint approaches. We have therefore investigated the potential of combining the Herpes OV (rQNestin 34.5) with immune checkpoint inhibition in glioblastoma models. rQNestin 34.5 is an OV with enhanced potency and tumor specificity, which will be tested in a Phase1 trial for recurrent glioblastoma in the near future. In vitro studies showed that the immune checkpoint ligand PD-L1 is expressed across a panel of human conventional and stem-like glioblastoma-derived cells (GSCs) and that cell surface PD-L1 is consistently up-regulated 24 hours after infection with rQNestin 34.5. This effect is most pronounced in GSCs of the mesenchymal subclass compared with proneural, and was not observed with other inducers of cell death such as staurosporine, and therefore may be due to direct effects of the OV treatment. We then showed that PD-L1 levels in glioblastoma cells are linked to increases of cytokine levels (i.e. interferon-g). These studies show that infection of cells with rQNestin 34.5 could lead to increased PD-L1 expression, thus providing a strong rationale for co-administration of OV with immune checkpoint blockade. Our initial studies using this combinatorial approach in immunocompetent mouse models demonstrate a significant and striking benefit of combined treatment with rQNestin34.5 and anti-PD-1 antibodies. This data suggests that immune checkpoint blockade combined with OV treatment should be developed for future clinical trials in glioblastoma.
Acute Splenic Sequestration in Sickle Cell Disease (SCD): Still a Life Threatening Complication
Authors: Valentine Brousse, Emmanuelle Lesprit, Francoise Bernaudin, Marie-Helene Odievre, Corinne Guitton, Beatrice Quinet, Silvana Dangiolo, Mariane De Montalembert
Journal: Blood (2008)
NIMG-51T1-HYPERINTENSE LESIONS AS A PREDICTOR OF SURVIVAL IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ON BEVACIZUMAB
Authors: Erin Morgan, Sean Symons, Chris Heyn, Pedro Carrera, Julia Keith, Todd Mainprize, Claire Moroney, Christina Mueller, Arjun Sahgal, Hany Soliman, May Tsao, James Perry
Journal: Neuro-Oncology (2015)
Patterns of Individual Tumor Response Testing (ITRT) and Bone Marrow Minimal Residual Disease (MRD) On Day 15 of Therapy in Childhood Precursor-B-Lineage Acute Lymphoblastic Leukemia (ALL): MRD and Ex Vivo Drug Resistance Have Similar Predictive Value of Relapse.
Authors: Jan Styczynski, Anna Jaworska-Posadzy, Malgorzata Kubicka, Robert Debski, Beata Kurylo-Rafinska, Beata Kolodziej, Monika Pogorzala, Magdalena Piatkowska, Krzysztof Czyzewski, Mariusz Wysocki
Journal: Blood (2012)
DERBI: A Digital Method to Help Researchers Offer “Right-to-Know” Personal Exposure Results
Authors: Katherine E. Boronow, Herbert P. Susmann, Krzysztof Z. Gajos, Ruthann A. Rudel, Kenneth C. Arnold, Phil Brown, Rachel Morello-Frosch, Laurie Havas, Julia Green Brody
Journal: Environmental Health Perspectives (2017)

Summary:Researchers and clinicians in environmental health and medicine increasingly show respect for participants and patients by involving them in decision-making. In this context, the return of personal results to study participants is becoming ethical best practice, and many participants now expect to see their data. However, researchers often lack the time and expertise required for report-back, especially as studies measure greater numbers of analytes, including many without clear health guidelines. In this article, our goal is to demonstrate how a prototype digital method, the Digital Exposure Report-Back Interface (DERBI), can reduce practical barriers to high-quality report-back. DERBI uses decision rules to automate the production of personalized summaries of notable results and generates graphs of individual results with comparisons to the study group and benchmark populations. Reports discuss potential sources of chemical exposure, what is known and unknown about health effects, strategies for exposure reduction, and study-wide findings. Researcher tools promote discovery by drawing attention to patterns of high exposure and offer novel ways to increase participant engagement. DERBI reports have been field tested in two studies. Digital methods like DERBI reduce practical barriers to report-back thus enabling researchers to meet their ethical obligations and participants to get knowledge they can use to make informed choices.
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Authors: Auvro R. Mridha, Alexander Wree, Avril A.B. Robertson, Matthew M. Yeh, Casey D. Johnson, Derrick M. Van Rooyen, Fahrettin Haczeyni, Narci C.-H. Teoh, Christopher Savard, George N. Ioannou, Seth L. Masters, Kate Schroder, Matthew A. Cooper, Ariel E. Feldstein, Geoffrey C. Farrell
Journal: Journal of Hepatology (2017)
Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.
Authors: Lisa Hicks, Rena Buckstein, Joy Mangel, Eugenia Piliotis, Kevin Imrie, Matthew C. Cheung, David E. Spaner, Marciano D. Reis, Zeina Ghorab, Violet Milliken, Nancy Pennell, Neil Berinstein
Journal: Blood (2006)
Pulmonary diffusing capacity and the risk of fractures in patients with chronic obstructive pulmonary disease (COPD)
Authors: Ekaterina Kochetova
Journal: European Respiratory Journal (2014)

Objective: to study pulmonary diffusing capacity (DLCO) and the risk of fractures in patients with chronic obstructive pulmonary disease (COPD).

Material and Methods: 125 patients with chronic obstructive pulmonary disease (COPD) were observed. The investigated group was made by the men having the long experience of smoking. Smoker index was 240. The average age was 61.4 ± 6.4 years. The patients received basic therapy system glucocorticoids have been excluded from the research. Research of function of external breath was studied with multimodular installation of type «Master-Lab/Jaeger». Pulmonary diffusing capacity (DLCO) was studied. Research of mineral density of a bone fabric was studied with the method x-ray absorbtiometry with the densitometer « Lunar DPX-NT». The assessment of risk of osteoporotic fractures were calculated by means of the computer program FRAX.

Results: The patients were divided into 3 groups: DLCO   60%. The high risk of hip fracture (> 3) in program FRAX was detected in 62.5% of patients with a sharp decrease of DLCO   60% the high risk of hip fracture was detected in 24.24% of patients. The correlation coefficient between DLCO / VA and the risk of hip fracture was r -0,44 (p <0.05).

Conclusions: decrease of pulmonary diffusing capacity has an important role in the progression of the risk of fractures in patients with COPD.
Fundamental differences between perception and cognition aside from cognitive penetrability
Authors: Graeme S. Halford, Trevor J. Hine
Journal: Behavioral and Brain Sciences (2016)

Abstract Fundamental differences between perception and cognition argue that the distinction can be maintained independently of cognitive penetrability. The core processes of cognition can be integrated under the theory of relational knowledge. The distinguishing properties include symbols and an operating system, structure-consistent mapping between representations, construction of representations in working memory that enable generation of inferences, and different developmental time courses.
AIDS-related B-cell lymphoma: Outcome correlates with differentiation profiles assessed by immunophenotyping
Authors: C. Hoffmann, C. Schrader, D. Janssen, E. Wolf, R. Parwaresch, M. Vierbuchen, K. Ernestus, H.-A. Horst, G. Fatkenheuer, M. Tiemann
Journal: Journal of Clinical Oncology (2005)

6579 Background: In HIV-1 infected patients, AIDS-related lymphoma (ARL) remains one of the most frequent AIDS-defining illnesses (ADI). Little is known about the differentiation profiles in ARL and their relation to the clinical course. Methods: Paraffin embedded sections of 89 ARL cases diagnosed during 1989–2004 were stained immunohistochemically with antibodies to CD3, CD10, CD20, CD38, CD138/Syn-1, MUM1/IRF4, BCL-2, BCL-6 and Ki-67. Expression profiles were correlated with clinical data and with clinical course. Results: Expression of CD10 and CD20 were associated with better overall survival (OS, p=0.009 and p=0.04, respectively). Expression of CD20 was associated with longer disease-free survival (DFS, p=0.03), whereas expression of CD138/Syn-1 was associated with shorter DFS (p=0.03). OS and DFS were worse in patients with immunophenotypic profiles related to post-germinal center (GC) differentiation when compared to GC differentiation. This was particular the case in patients with an activated non-GC B-cell pattern (expression of MUM1/IRF4 and/or CD138/syn-1 but not of the GC B-cell markers CD10 and BCL-6) of the ARL (p=0.01). When controlled for age-adjusted International Prognostic Index, prior ADI and year of ARL diagnosis, expression of CD20 and CD10 remained significantly associated with improved OS in multivariate analysis. Expression of CD10 was associated with a preserved immunocompetence whereas CD20 expression was associated with an elevated lactate dehydrogenase level. CD20 expression was less frequent in patients developing ARL while on highly active antiretroviral therapy (HAART, p=0.04). Conclusions: Our data indicate that CD10 and CD20 expression are important predictors of clinical outcome in ARL. We also demonstrate a clinical relevance of immunohistochemical expression profiles which correspond to distinct stages of physiologic B-cell development. No significant financial relationships to disclose.
Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia
Authors: Christian Buske, Shalal Sadullah, Efsthatios Kastritis, Giulia Benevolo, Ramon Garcia-Sanz, Lukasz Bolkun, Xavier Leleu, Wolfgang Willenbacher, Roman Hajek, Ellen van der Spek, Mei Cheng, Thorsten Graef, Meletios A. Dimopoulos
Journal: Blood (2015)
Defucosylated Anti-CCR4 Monoclonal Antibody Exerts Potent ADCC against Primary ATLL Cells Mediated by Autologous Human Immune Cells in NOD/Shi-Scid, IL-2Rγnull Mice In Vivo.
Authors: Asahi Ito, Takashi Ishida, Atae Utsunomiya, Fumihiko Sato, Fumiko Mori, Hiroki Yano, Atsushi Inagaki, Susumu Suzuki, Hisashi Takino, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki, Ryuzo Ueda
Journal: Blood (2009)
Bone Mineral Density Utilization in Patients with Newly Diagnosed Multiple Myeloma: A Single Center Experience
Authors: Eli Muchtar, Adi Zelig, Eyal Robenshtok, Tzippy Shochat, Nino Oniashvili, Irina Amitai, Pia Raanani, Hila Magen
Journal: Blood (2015)
Alu-Element Insertion in Pklr Gene As a Novel Cause of Severe Hereditary Nonspherocytic Hemolytic Anemia
Authors: Harry Lesmana, Lisa Dyer, Ping Zhou, Xia Li, James Denton, Satheesh Chonat, Kejian Zhang, Robert J. Hopkin, Theodosia A. Kalfa
Journal: Blood (2015)
Familial associations of lymphoma and myeloma with autoimmune diseases
Authors: K Hemminki, A Försti, K Sundquist, J Sundquist, X Li
Journal: Blood Cancer Journal (2017)

Many B-cell neoplasms are associated with autoimmune diseases (AIDs) but most evidence is based on a personal rather than a family history of AIDs. Here we calculated risks for non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and multiple myeloma (MM) when family members were diagnosed with any of 44 different AIDs, or, independently, risk for AIDs when family members were diagnosed with a neoplasm. A total of 64 418 neoplasms and 531 155 AIDs were identified from Swedish nationwide health care records. NHL was associated with a family history of five AIDs, all increasing the risk, HL was associated with one AID increasing and three AIDs decreasing the risk while MM had no association. A family history of NHL was associated with eight, HL with seven and MM with seven different AIDs, nine increasing and 13 decreasing the risk. The present family data on B-cell neoplasms and AIDs show an approximately equal number of associations for risk increase and risk decrease, suggesting that inherited genes or gene-environment interactions may increase the risk or be protective. These results differed from published data on personal history of AID, which only report increased risks, often vastly higher and for different AIDs compared with the present data.
Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed/Refractory T Cell Lymphomas in Adults: A Survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Authors: Steven Le Gouill, Jean-noël Milpied, Jean-paul Vernant, Norbert Ifrah, Françoise Mechinaud, Nicole Gratecos, Zina Chir, Jean-luc Harousseau, Gérard Socié, Corinne Haioun, Didier Blaise, Mauricette Michallet
Journal: Blood (2006)